Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus

Purpose of reviewTo provide an overview behind the concept and recent advances of low-dose interleukin-2 (IL-2) therapy in systemic lupus erythematosus (SLE).Recent findingsA disruption of regulatory T cell homeostasis caused by an acquired deficiency of IL-2 is a crucial event in the pathogenesis o